Part, Chapter, Paragraph
1 II, 5. 1. 1 | cardio-vascular diseases.~ ~· Multiple Sclerosis~Multiple Sclerosis is a
2 II, 5. 1. 1 | Multiple Sclerosis~Multiple Sclerosis is a complex multifactorial
3 II, 5. 5. 3 | Downs Syndrome, tuberous sclerosis and Fragile X Syndrome,
4 II, 5. 5. 3 | 5.5.3.5 Multiple sclerosis~ ~
5 II, 5. 5. 3 | Introduction~ ~Multiple sclerosis (MS) is a chronic progressive
6 II, 5. 5. 3 | follow. The Danish Multiple Sclerosis Registry (DMSR) has collected
7 II, 5. 5. 3 | European Database for Multiple Sclerosis (EDMUS) has been available
8 II, 5. 5. 3 | Concerted Action for Multiple Sclerosis funded by the European Commission (
9 II, 5. 5. 3 | Norwegian National Multiple Sclerosis Registry was established
10 II, 5. 5. 3 | at the Norwegian Multiple Sclerosis National Competence Centre,
11 II, 5. 5. 3 | Prevalence of Multiple Sclerosis in selected EUGLOREH Countries~ ~
12 II, 5. 5. 3 | per 100 000) of Multiple Sclerosis in selected EUGLOREH Contries
13 II, 5. 5. 3 | per 100 000) of Multiple Sclerosis in selected EUGLOREH Countries,
14 II, 5. 5. 3 | 100 000/year) of Multiple Sclerosis in Europe~ ~ ~Systematic
15 II, 5. 5. 3 | Proportion of Multiple Sclerosis patients by disease course
16 II, 5. 5. 3 | Proportion of Multiple Sclerosis patients by disease severity (
17 II, 5. 5. 3 | EU citizens with multiple sclerosis has not yet been analysed;
18 II, 5. 5. 3 | however, the onset of multiple sclerosis often occurs at the prime
19 II, 5. 5. 3 | towards people with multiple sclerosis within the European Union)
20 II, 5. 5. 3 | British person with Multiple Sclerosis, Louise McVay. This report
21 II, 5. 5. 3 | by the European Multiple Sclerosis Platform and all EU Multiple
22 II, 5. 5. 3 | Platform and all EU Multiple Sclerosis Societies. Health Departments
23 II, 5. 5. 3 | the management of Multiple Sclerosis;~· A shared agenda in MS
24 II, 5. 5. 3 | Good Practice” on Multiple Sclerosis and its reference documents.
25 II, 5. 5. 3 | European Map of Multiple Sclerosis, (ww g)~The European Map
26 II, 5. 5. 3 | MS patients. The multiple sclerosis therapy consensus group (
27 II, 5. 5. 3 | for People with Multiple Sclerosis in Europe by the European
28 II, 5. 5. 3 | by the European Multiple Sclerosis Platform and RIMS, Rehabilitation
29 II, 5. 5. 3 | Rehabilitation in Multiple Sclerosis (Battaglia et al, 2004).~
30 II, 5. 5. 3 | foremost experts in Multiple Sclerosis Rehabilitation in Europe;
31 II, 5. 5. 3 | severely affected with multiple sclerosis ( Haffenden et al, 2006).~
32 II, 5. 5. 3 | constitute the European Multiple Sclerosis Platform (EMSP). EMSP is
33 II, 5. 5. 3 | international level, the Multiple Sclerosis International Federation (
34 II, 5. 5. 3(26)| to people with multiple sclerosis within the European Union~
35 II, 5. 5. 3 | entitled MS-ID (Multiple Sclerosis – Information Dividend)
36 II, 5. 5. 3 | citizens affected by Multiple Sclerosis (MS). It will create a standardised
37 II, 5. 5. 3 | epidemiology of multiple sclerosis in Europe; good practice
38 II, 5. 5. 3 | 2004): Report of multiple sclerosis centers. Cephalalgia Hungarica
39 II, 5. 5. 3 | for Persons with Multiple Sclerosis in Europe~Baumhackl U, Eibl
40 II, 5. 5. 3 | Prevalence of multiple sclerosis in Austria. Results of a
41 II, 5. 5. 3 | Epidemiologic survey of multiple sclerosis in Mures County, Romania.
42 II, 5. 5. 3 | The prevalence of multiple sclerosis, distribution of clinical
43 II, 5. 5. 3 | history of untreated multiple sclerosis in Iceland. A total population-based
44 II, 5. 5. 3 | L et al (1998): Multiple sclerosis in Móstoles, central Spain.
45 II, 5. 5. 3 | 2004): Report of multiple sclerosis center in Lodz. Cephalalgia
46 II, 5. 5. 3 | Epidemiology of multiple sclerosis in Russia and other of the
47 II, 5. 5. 3 | Boiko AN (1994): Multiple sclerosis prevalence in Russia and
48 II, 5. 5. 3 | Lauer K (eds): Multiple Sclerosis in Europe: An Epidemiological
49 II, 5. 5. 3 | of patients with multiple sclerosis in Denmark: a nationwide,
50 II, 5. 5. 3 | Damish patients with multiple sclerosis. Brain 127:844-850.~Brønnum-Hansen
51 II, 5. 5. 3 | Vandvik B (2001): Multiple sclerosis in Oslo, Norway: prevalence
52 II, 5. 5. 3 | European database for multiple sclerosis. J Neurol Neurosurg Psychiatr
53 II, 5. 5. 3 | Establishment and use of multiple sclerosis registers – EDMUS. Ann Neurol
54 II, 5. 5. 3 | of disability in multiple sclerosis. N Engl J Med 343:1430–1438.~
55 II, 5. 5. 3 | irreversible disability in multiple sclerosis: an amnesic process. Brain
56 II, 5. 5. 3 | Midgard R (2004): Multiple sclerosis in Nord-Trøndelag County,
57 II, 5. 5. 3 | The prevalence of multiple sclerosis in the District of Santarem,
58 II, 5. 5. 3 | et al (2002): Multiple sclerosis in Malta in 1999: an update.
59 II, 5. 5. 3 | Natural history of multiple sclerosis. In: Compston A (ed). McAlpine’
60 II, 5. 5. 3 | ed). McAlpine’s Multiple Sclerosis, 3rd edition. New York:
61 II, 5. 5. 3 | Environmental factors and multiple sclerosis. Lancet 7;268-277.~Ekestern
62 II, 5. 5. 3 | Mortality from multiple sclerosis in Austria 1970–2001: dynamics,
63 II, 5. 5. 3 | Diagnosis of multiple sclerosis: comparison of the Poser
64 II, 5. 5. 3 | K (eds) (1994): Multiple Sclerosis in Europe: An Epidemiological
65 II, 5. 5. 3 | and Research in Multiple Sclerosis. Prague, Czech Republic
66 II, 5. 5. 3 | The prevalence of multiple sclerosis in Tayside, Scotland: do
67 II, 5. 5. 3 | The prevalence of multiple sclerosis in the Leeds Health Authority.
68 II, 5. 5. 3 | and mortality of multiple sclerosis in Leeds. J Neurol 249:260-
69 II, 5. 5. 3 | Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil 65:
70 II, 5. 5. 3 | et al (1996): Multiple sclerosis in Italy. A reappraisal
71 II, 5. 5. 3 | the incidence of multiple sclerosis in Hordaland County, Norway.
72 II, 5. 5. 3 | et al (2000): Multiple sclerosis in North Norway, and first
73 II, 5. 5. 3 | severely affected with multiple sclerosis. [On-line publication available
74 II, 5. 5. 3 | of the number of multiple sclerosis patients in germany]. Nervenartz
75 II, 5. 5. 3 | Symptomatic Treatment of Multiple Sclerosis. Multiple Sclerosis Therapy
76 II, 5. 5. 3 | Multiple Sclerosis. Multiple Sclerosis Therapy Consensus Group (
77 II, 5. 5. 3 | of the German Multiple Sclerosis Society. Eur Neurol. 2006;
78 II, 5. 5. 3 | 2004): Report of multiple sclerosis center at Charles University.
79 II, 5. 5. 3 | Epidemiology of multiple sclerosis in Czechoslovakia. In: Battaglia
80 II, 5. 5. 3 | An Update on Multiple Sclerosis. Monduzzi Editore, Bologna,
81 II, 5. 5. 3 | Epidemiology of multiple sclerosis: incidence and prevalence
82 II, 5. 5. 3 | based on the Danish Multiple Sclerosis Registry. Acta Neurol Scand
83 II, 5. 5. 3 | Incidence of multiple sclerosis in Denmark 1948-1982: a
84 II, 5. 5. 3 | 1999): The Danish Multiple Sclerosis Registry: a 50-year follow-up.
85 II, 5. 5. 3 | 2001). The Danish Multiple Sclerosis Registry. History, data
86 II, 5. 5. 3 | investigation of multiple sclerosis in Slovenia. In: Firnhaber
87 II, 5. 5. 3 | Lauer K (eds): Multiple Sclerosis in Europe: An Epidemiological
88 II, 5. 5. 3 | 1988): Fatigue in multiple sclerosis. Arch Neurol 45:435-437.~
89 II, 5. 5. 3 | neurological impairment in multiple sclerosis and expanded disability
90 II, 5. 5. 3 | disproportion of multiple sclerosis in Czechoslovakia from the
91 II, 5. 5. 3 | Lauer K (eds): Multiple Sclerosis in Europe: An Epidemiological
92 II, 5. 5. 3 | clinical course of multiple sclerosis: results from an international
93 II, 5. 5. 3 | survey. National Multiple Sclerosis Society (USA): Advisory
94 II, 5. 5. 3 | on New Agents in Multiple Sclerosis. Neurology 46:907-911.~Lucchinetti
95 II, 5. 5. 3 | Distinct patterns of multiple sclerosis pathology indicates heterogeneity
96 II, 5. 5. 3 | diagnostic criteria for multiple sclerosis: guidelines from the International
97 II, 5. 5. 3 | the Diagnosis of Multiple Sclerosis. Annals of Neurology 50:
98 II, 5. 5. 3 | epidemiologic study of multiple sclerosis in Northern Ireland. Neurology
99 II, 5. 5. 3 | primary progressive multiple sclerosis in Northern Ireland, UK.
100 II, 5. 5. 3 | and handicap in multiple sclerosis: a population-based study.
101 II, 5. 5. 3 | the prevalence of multiple sclerosis in Ireland, an effect of
102 II, 5. 5. 3 | Dean G (1991): Multiple sclerosis in Cyprus. J Neurol Sci
103 II, 5. 5. 3 | Prevalence of multiple sclerosis in Bulgaria. Neuroepidemiology
104 II, 5. 5. 3 | the person with multiple sclerosis. In: Compston A. (ed). McAlpine’
105 II, 5. 5. 3 | ed). McAlpine’s Multiple sclerosis. China: Churchill Livingston
106 II, 5. 5. 3 | and incidence of multiple sclerosis: an epidemiological study
107 II, 5. 5. 3 | Lauer K (eds): Multiple Sclerosis in Europe: An Epidemiological
108 II, 5. 5. 3 | Prevalence of multiple sclerosis in the province of Teruel,
109 II, 5. 5. 3 | Incidence of multiple sclerosis in Dijon, France : a population-based
110 II, 5. 5. 3 | 156-159.~MSTCG (Multiple sclerosis therapy consensus group)
111 II, 5. 5. 3 | immunomodulatory therapy of multiple sclerosis. Update. Nervenarzt 77:1506-
112 II, 5. 5. 3 | German)~MSTCG (Multiple sclerosis therapy consensus group) (
113 II, 5. 5. 3 | The Norwegian Multiple Sclerosis National Competence Centre
114 II, 5. 5. 3 | Centre and National Multiple Sclerosis registry—a resource for
115 II, 5. 5. 3 | and incidence of multiple sclerosis in Catania, Sicily. Neurology
116 II, 5. 5. 3 | Weinshenker BG (2000): Multiple sclerosis. N Engl J Med 343;938-952.~
117 II, 5. 5. 3 | high frequency of multiple sclerosis in Croatia and Slovenia.
118 II, 5. 5. 3 | Epidemiological data of multiple sclerosis in the province of Evros,
119 II, 5. 5. 3 | diagnostic criteria for multiple sclerosis: guidelines for research
120 II, 5. 5. 3 | Increasing incidence of multiple sclerosis in South Lower Saxony, Germany.
121 II, 5. 5. 3 | Epidemiology of multiple sclerosis in the region of Szczecin:
122 II, 5. 5. 3 | Epidemiological aspects of multiple sclerosis: a comparative study of
123 II, 5. 5. 3 | G et al (2001): Multiple sclerosis epidemiology in Sardinia:
124 II, 5. 5. 3 | Increasing incidence of multiple sclerosis in the province of Sassari,
125 II, 5. 5. 3 | epidemiology of multiple sclerosis in Europe. Eur J Neurol
126 II, 5. 5. 3 | Epidemiology of multiple sclerosis. In: Raine CS, McFarland
127 II, 5. 5. 3 | Hohlfeld H (eds). Multiple sclerosis. A comprehensive text. Elsevier,
128 II, 5. 5. 3 | Increasing frequency of multiple sclerosis in Padova, Italy: a 30-year
129 II, 5. 5. 3 | Compston DAS (1995): multiple sclerosis in the North Cambridgeshire
130 II, 5. 5. 3 | clinical diagnosis of multiple sclerosis. Neurology 26:20-22.~Rothwell
131 II, 5. 5. 3 | and prevalence of multiple sclerosis in South East Scotland:
132 II, 5. 5. 3 | Epidemiology of multiple sclerosis: a critical overview. Can
133 II, 5. 5. 3 | Occurrence of multiple sclerosis in central Finland: a regional
134 II, 5. 5. 3 | the incidence of multiple sclerosis in Finland 1979-1993. Neuroepidemiology
135 II, 5. 5. 3 | Increasing prevalence of multiple sclerosis in Finland. Acta Neurol
136 II, 5. 5. 3 | Wikström J (2003): Multiple sclerosis in Finland: incidence trends
137 II, 5. 5. 3 | Prevalence of multiple sclerosis in Västerbotten County in
138 II, 5. 5. 3 | prevalence (1997): of multiple sclerosis in Västerbotten County in
139 II, 5. 5. 3 | characteristics of multiple sclerosis in Västerbotten County in
140 II, 5. 5. 3 | Prevalence of multiple sclerosis in Valladolid, northern
141 II, 5. 5. 3 | Prevalence of multiple sclerosis in the L’Aquila district,
142 II, 5. 5. 3 | the lesions of multiple sclerosis. N Engl J Med 338:278-285.~
143 II, 5. 5. 3 | International Federation of Multiple Sclerosis) [on line publication available
144 II, 5. 5. 3 | Prevalence of multiple sclerosis in Flanders, Belgium. Neuroepidemiology
145 II, 5. 5. 3 | the prevalence of multiple sclerosis in French farmers. J Neurol
146 II, 5. 5. 3 | epidemiological studies on multiple sclerosis. Neuroepidemiology 22:65-
147 II, 5. 5. 3 | Clinically Definite Multiple Sclerosis~CPMS~Clinically Probable
148 II, 5. 5. 3 | Clinically Probable Multiple Sclerosis~CP-MS~Chronic Progressive
149 II, 5. 5. 3 | Chronic Progressive Multiple Sclerosis~CNS~Central Nervous System~
150 II, 5. 5. 3 | Years~DMSR~Danish Multiple Sclerosis Registry~EDSS~Expanded Disability
151 II, 5. 5. 3 | Agency~EMSP~European Multiple Sclerosis Platform~EU~European Union~
152 II, 5. 5. 3 | Laboratory-Supported Definite Multiple Sclerosis~LSPMS~Laboratory-Supported
153 II, 5. 5. 3 | Laboratory-Supported Probable Multiple Sclerosis~MRI~Magnetic Resonance Imaging~
154 II, 5. 5. 3 | Resonance Imaging~MS~Multiple Sclerosis~MS-ID~Multiple Sclerosis
155 II, 5. 5. 3 | Sclerosis~MS-ID~Multiple Sclerosis Information Dividend~MSIF~
156 II, 5. 5. 3 | Information Dividend~MSIF~Multiple Sclerosis International Federation~
157 II, 5. 5. 3 | Federation~MSTCG~Multiple Sclerosis Therapy Consensus Group~
158 II, 5. 5. 3 | Primary Progressive Multiple Sclerosis~PR-MS~Progressive-Relapsing
159 II, 5. 5. 3 | Progressive-Relapsing Multiple Sclerosis~RR-MS~Relapsing-Remitting
160 II, 5. 5. 3 | Relapsing-Remitting Multiple Sclerosis~SC~Subcutaneously~SP-MS~
161 II, 5. 5. 3 | Secondary Progressive Multiple Sclerosis~UK~United Kingdom~WHO~World
162 II, 5. 6. 3 | osteophytes and subchondral bone sclerosis) and thickening of the capsule.
163 II, 5. 6. 3 | changes (loss of joint space, sclerosis and osteophytes) that have
164 IV, 13. 2. 2 | total DALY for Multiple Sclerosis in Europe is 307 000 years
165 Key, Ap5. 0. 0 | school~schools~scleroderma~sclerosis~sedentariness~seizure~seizures~
